- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00638443
Lumbar Stenosis Outcomes Research (LUSTOR) (LUSTOR)
May 11, 2016 updated by: John Markman, University of Rochester
Lumbar Stenosis Outcomes Research (LUSTOR)- A Randomized, Double-blind, Cross-over Trial of Pregabalin vs. Diphenhydramine in Patients With Lumbar Spinal Stenosis and Neuropathic Low Back Pain
The primary objective of the proposed pilot study is to determine the efficacy of pregabalin in prolonging the time to onset of pain and reducing the severity of pain associated with walking in patients with neurogenic claudication.
Neurogenic claudication is defined as movement induced leg pain, numbness, heaviness, or vague discomfort in part or all of one or both legs provoked with walking and standing and relieved by sitting, squatting, or forward flexion posturing.
The secondary objective is to examine the functional benefit of pregabalin with respect to improvement in duration and distance of walking.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Subjects were randomized into one of two treatment sequences: pregabalin/active placebo or active placebo/pregabalin.
Each arm lasted 10 days, with a washout period of 10 days between treatments.
Pregabalin was administered as a standardized two step titration, starting at 75mg twice daily up to a maximum daily dose of 150mg twice daily; and likewise, diphenhydramine (active placebo) was administered starting at 6.25mg twice daily up to a maximum daily dose of 12.5mg twice daily.
The primary endpoint was time to first symptoms of moderate intensity (NRS ≥ 4/10) during treadmill ambulation.
Ambulation assessment was performed during the screening visit, and on day 10 of each period to evaluate pain intensity associated with walking as well as distance covered by the patients.
Quantitative assessment of ambulation was conducted on a treadmill at 0° ramp incline at 1.2 miles per hour (mph).
Measurement of self-reported symptom severity using the NRS at baseline, and every 30 seconds for a maximum of 15 minutes was recorded.
The following information was also recorded: time to first symptoms, total ambulation time.
The examination was stopped after 15 minutes or at the onset of severe symptoms.
Severe symptoms were defined as the level of discomfort that would make patients stop walking in usual life situations.
No one was encouraged or prompted to continue walking beyond this point.
Patients were instructed to walk with an upright posture.
They were not permitted to lean forward or hold onto the handrails during the examination.
Secondary outcome measures included area under the curve of present pain intensity with ambulation at each specified time point, final pain intensity with walking, walking tolerance, time to return to baseline pain level after ambulation, as well as the results of a series of pain related questionnaires including: Visual Analog Scale (VAS), Patient Global Assessment (PGA), NRS, Roland Morris Disability Questionnaire (RMDQ), modified Brief Pain Inventory short form (mBPI-sf), Oswestry Disability Index (ODI), and Swiss Spinal Stenosis (SSS).
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Rochester, New York, United States, 14618
- 2180 South Clinton Avenue
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must present with clinical symptoms of neurogenic claudication (neurogenic claudication is defined as movement induced leg pain, numbness, heaviness, or vague discomfort in part or all of one or both legs provoked with walking and standing and relieved by sitting, squatting, or forward flexion posturing) and endorse limitation of walking tolerance due to these symptoms
- Numeric Rating Scale (NRS) for pain greater than or equal to 6 in response to the following questions: "Circle one number (from 0=no pain to 10=worst pain)-How would you rate the worst leg and lower back pain you experienced during walking last week?"
- Patients must have confirmatory imaging by MRI or CT scan demonstrating at least one level of lumbar spinal stenosis within 1 year
- Duration of symptoms > 3 months
- Age > 50 years; male or female
Exclusion Criteria:
- Past or present existence of movement disorder, e.g., Parkinsonism,or a neurologic disease that might affect the ability to ambulate (e.g., signs/symptoms of cauda equina compression)
- Cognitive impairment preventing full understanding or participation in the study
- Peripheral vascular disease
- Moderate to severe arthritis of the knee or hip that might severely compromise ambulation
- Past or present lower extremity peripheral vascular disease
- Serious concomitant medical illness (e.g., heart disease) that might impair ambulation assessment
- Previous lumbar surgery for spinal stenosis (laminectomy with or without fusion) within the past 2 years
- Prior treatment with study drug for neurogenic claudication
- Severe psychiatric disorder
- Mean time to severe symptoms > 15 minutes.
- Epidural steroid treatment within the last three months
- Ongoing treatment with gabapentin
- Hypersensitivity or allergic reaction to diphenhydramine
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Pregabalin then Diphenhydramine
Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days; no drug for 7 days; diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
|
Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
Other Names:
diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
Other Names:
|
Other: Diphenhydramine then Pregabalin
diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days; no drug for 7 days; pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
|
Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
Other Names:
diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to First Symptoms of Moderate Pain
Time Frame: 10 days
|
Using the Numeric Rating Scale (NRS) (0=no pain, 10=worst pain imaginable)the time to first symptoms (Tfirst) with a NRS score greater than or equal to 4 (moderate pain level), with treadmill ambulation was measured.
|
10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Final Pain as Measured by NRS
Time Frame: 10 days
|
Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed.
At defined intervals subjects were asked what their pain level was according to the NRS.
When the subject reached their maximum distance, they were asked their NRS score.
This was recorded as final pain intensity.
Using the Numeric Rating Scale (NRS) (0=no pain, 10=worst pain imaginable)the time to first symptoms (Tfirst) with a NRS score greater than or equal to 4 (moderate pain level), with treadmill ambulation was measured.
|
10 days
|
Total Distance
Time Frame: 10 days
|
Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed.
When the subject reached their maximum distance, the treadmill testing was stopped.
This was recorded as total distance based on number of minutes and seconds walked.
Minutes was converted to meters based on calculation of defined speed of the treadmill.
|
10 days
|
Recovery Time
Time Frame: 10 days
|
After the subject completed the treadmill test they were asked to immediately return to the seated position.
At this point a timer was started.
When the subjects pain level returned to baseline (level of pain subject felt in a seated position before walking) the time was stopped.
This was recorded as recovery time.
Maximum recovery time is 15 minutes.
|
10 days
|
Area Under the Curve
Time Frame: 10 days
|
Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed.
At defined intervals (every 30 seconds) subjects were asked what their pain level was according to the NRS.
The area under the curve of present pain intensity multiplied by the amount of time the subject walked.
|
10 days
|
Visual Analog Scale (VAS)
Time Frame: 10 days
|
The VAS asked subjects to place a mark indicative of their low back pain during the past day on a 100mm line, with 0mm representing no pain and 100mm representing extreme pain.
|
10 days
|
Oswestry Disability Index (ODI) Score
Time Frame: 10 days
|
The ODI is a set of 10 questions each with five choices (maximum score of 5 points per question) designed to determine how back pain has affected the ability to manage everyday life (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, social life, traveling, and change positions).
A total score range of 0-50; score of 0 indicates no disability and a score of 50 would indicate 100% disability.
|
10 days
|
Swiss Spinal Stenosis (SSS) Score- Symptom Severity
Time Frame: 10 days
|
The SSS is a series of questions asking about symptom severity, physical function, and satisfaction.
The symptom severity section is a set of 7 questions (maximum score is 5 points per question) and asks to rate pain for each question based on no pain, mild, moderate, severe or very severe pain.
The total score (maximum=35) is added up and divided by seven.
The maximum score for the symptom severity section (score=5) indicates very severe symptom severity.
|
10 days
|
Swiss Spinal Stenosis- Physical Function
Time Frame: 10 days
|
The SSS is a series of questions asking about symptom severity, physical function, and satisfaction.
The physical function section is a series of 5 questions (maximum 4 points per question) and asks to rate function for each question based on comfortably, sometimes with pain, always with pain, no functional ability.
The total score (max=20) is divided by five.
The maximum score for the physical function section (max=4) indicates no ability to function.
|
10 days
|
Modified Brief Pain Inventory (mBPI)- Interference Score
Time Frame: 10 days
|
The mBPI is a series of questions that rates the severity and impact of pain on daily function.
The questionnaire is made up of 4 pain severity items using the NRS scale, and seven pain interference sub-scales.
The final interference score is an average of the seven sub-scales (0 indicating no interference and 10 indicating complete interference).
|
10 days
|
Roland Morris Disability Questionnaire
Time Frame: 10 days
|
The RMDQ consists of 24 yes/no statements about activity limitations due to back pain.
These questions center on movement, ambulation, and self-care activities.
Positive (yes) answers each contribute 1 point to cumulative score with total scores ranging from 0 (no disability) to 24 (severely disabled).
|
10 days
|
Patient Global Assessment (PGA)
Time Frame: 10 days
|
Subjects were asked to rate their low back pain according to the PGA.
PGA is the impact of disease activity.
PGA was measured on a 5-point scale, where 1=very good, 2=good, 3=fair, 4=poor, and 5=very poor.
|
10 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: John D Markman, M.D, University of Rochester
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Stucki G, Daltroy L, Liang MH, Lipson SJ, Fossel AH, Katz JN. Measurement properties of a self-administered outcome measure in lumbar spinal stenosis. Spine (Phila Pa 1976). 1996 Apr 1;21(7):796-803. doi: 10.1097/00007632-199604010-00004.
- Simon LS, Evans C, Katz N, Bombardier C, West C, Robbins J, Copley-Merriman C, Markman J, Coombs JH. Preliminary development of a responder index for chronic low back pain. J Rheumatol. 2007 Jun;34(6):1386-91.
- Markman JD, Dworkin RH. Ion channel targets and treatment efficacy in neuropathic pain. J Pain. 2006 Jan;7(1 Suppl 1):S38-47. doi: 10.1016/j.jpain.2005.09.008.
- Deen HG Jr, Zimmerman RS, Lyons MK, McPhee MC, Verheijde JL, Lemens SM. Test-retest reproducibility of the exercise treadmill examination in lumbar spinal stenosis. Mayo Clin Proc. 2000 Oct;75(10):1002-7. doi: 10.4065/75.10.1002.
- Deen HG, Zimmerman RS, Lyons MK, McPhee MC, Verheijde JL, Lemens SM. Use of the exercise treadmill to measure baseline functional status and surgical outcome in patients with severe lumbar spinal stenosis. Spine (Phila Pa 1976). 1998 Jan 15;23(2):244-8. doi: 10.1097/00007632-199801150-00019.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2008
Primary Completion (Actual)
March 1, 2010
Study Completion (Actual)
September 1, 2010
Study Registration Dates
First Submitted
March 12, 2008
First Submitted That Met QC Criteria
March 12, 2008
First Posted (Estimate)
March 19, 2008
Study Record Updates
Last Update Posted (Estimate)
June 20, 2016
Last Update Submitted That Met QC Criteria
May 11, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Musculoskeletal Diseases
- Pathological Conditions, Anatomical
- Spinal Diseases
- Bone Diseases
- Constriction, Pathologic
- Spinal Stenosis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics
- Antiemetics
- Gastrointestinal Agents
- Dermatologic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Hypnotics and Sedatives
- Anti-Anxiety Agents
- Anticonvulsants
- Anesthetics, Local
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Anti-Allergic Agents
- Sleep Aids, Pharmaceutical
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- Diphenhydramine
- Promethazine
- Pregabalin
Other Study ID Numbers
- 16697
- IIR#GA00818X (Other Identifier: Sponsor ID)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lumbar Spinal Stenosis
-
Johns Hopkins UniversityNorth American Spine SocietyCompletedLumbar Spinal Stenosis | Lumbar Spine Degeneration | Lumbar Spinal InstabilityUnited States
-
Azienda Usl di BolognaRecruitingLumbar Spinal Stenosis | Degenerative Lumbar Spinal StenosisItaly
-
Medipol UniversityWithdrawnLumbar Spinal Stenosis | Lumbar Disc Disease | Lumbar Spine Degeneration | Lumbar Spine InstabilityTurkey
-
University Hospital, Basel, SwitzerlandKlinik für Radiologie und Nuklearmedizin, University Hospital BaselCompletedLumbar Spinal Stenosis | Symptomatic Lumbar Spinal StenosisSwitzerland
-
Bursa City HospitalCompletedLumbar Spinal Stenosis | Lumbar Spine Degeneration | Lumbar Spine InstabilityTurkey
-
Xuanwu Hospital, BeijingRecruitingLumbar Disc Herniation | Lumbar Spinal Stenosis | Lumbar SpondylosisChina
-
Neurocenter of Southern SwitzerlandMaastricht University; Schulthess KlinikRecruitingLumbar Spinal Stenosis | Lumbar Spondylolisthesis | Spinal Disease | Lumbar InstabilitySwitzerland
-
University of Roma La SapienzaRecruitingLumbar Spinal Stenosis | Lumbar Spondylolisthesis | Lumbar Spine Degeneration | Lumbar Spine InstabilityItaly
-
Cantonal Hospital of St. GallenProf. Dr. Astrid Weyerbrock, Klinik für Neurochirurgie, Kantonsspital St.... and other collaboratorsCompletedLumbar Spinal Stenosis | Lumbar Disc Disease | Lumbar Spine DegenerationSwitzerland
-
Kyungpook National University HospitalCompletedDisk Herniated Lumbar | Spinal Stenosis LumbarKorea, Republic of
Clinical Trials on Pregabalin
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
AstraZenecaCompletedDiabetic Neuropathy, Painful; Diabetic NeuropathiesUnited States
-
Jiangsu HengRui Medicine Co., Ltd.UnknownPostherpetic NeuralgiaChina
-
EMSRecruitingNeuropathic PainBrazil
-
Hamilton Health Sciences CorporationMcMaster UniversityTerminated
-
Janssen-Cilag Ltd.Completed
-
The First Hospital of Jilin UniversityCompletedPain, Postoperative | Arthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipChina
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
University of British ColumbiaJuvenile Diabetes Research FoundationUnknown
-
Ziauddin UniversityCompletedPain, Nerve | Prolapsed Intervertebral DiscPakistan